Pricing Log in Create free account

CNS Pharmaceuticals, Inc. (CNSP) vs Karyopharm Therapeutics Inc. (KPTI)

CNS Pharmaceuticals, Inc. and Karyopharm Therapeutics Inc. are both Biotechnology companies. CNS Pharmaceuticals, Inc. and Karyopharm Therapeutics Inc. are of similar size ($8.0M and $7.9M). CNS Pharmaceuticals, Inc. has the higher net margin (0.00% vs −153.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, CNS Pharmaceuticals, Inc. leads on 8 and Karyopharm Therapeutics Inc. on 4.

Valuation

Metric CNSP KPTI Biotechnology median
P/E n/m n/m 8.50
P/S n/m 0.08 9.71
P/B 1.82 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 1.34 9.21
Earnings yield (486.39%) (3,634.56%) (33.15%)
Free cash flow yield (40.54%) (580.28%) (25.50%)

Profitability

Metric CNSP KPTI Biotechnology median
Gross margin 0.00% 95.89% 65.16%
Operating margin 0.00% (56.17%) 0.00%
Net margin 0.00% (153.28%) 0.00%
Free cash flow margin 0.00% (44.57%) 0.00%
Return on equity (106.62%) 78.98% (56.36%)
Return on assets (91.64%) (207.90%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CNSP KPTI Biotechnology median
Revenue growth (TTM) — 6.81% 6.02%
EPS growth (last fiscal year) 92.34% (98.37%) 30.26%
Revenue growth, 5-year CAGR — 6.21% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CNSP KPTI Biotechnology median
Debt to equity 0.00 (0.76) 0.00
Current ratio 5.86 0.79 4.72
Net debt to EBITDA 0.45 (2.03) 0.96

Dividend

Metric CNSP KPTI Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CNSP KPTI Biotechnology median
Market cap 7.88m 7.95m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack